2010年、IBCの主催により、創薬および新薬開発に関する第5回の学会が日本で開催されます

取り上げるテーマ、会場、日程、すべてが新しくなるこの学会にご期待下さい

国際的な提携、アジアの新興市場、日本国内の規制、革新的な研究開発の展望といったテーマを掲げて開催された第1回の大会から、タンパク質科学や抗体療法、初期創薬段階から概念実証(POC)段階までの期間短縮といったテーマに焦点を当てた前回の大会まで、この学会は、日本の製薬業界におけるさまざまなトレンドを追跡し、世界第2位の医薬品市場であるこの国の複雑なニーズを反映させる不断の取り組みを続けています。

日本のニーズに対応する最も的確な情報の提供という基本方針が設定された今回の学会では、小分子、抗体、タンパク薬物、オリゴヌクレオチド、ペプチドなどに加え、創薬や新薬開発、診断、マーケティングなどのテーマも取り上げられることになっており、事業規模の大小に関わらず、日本にあるすべての製薬会社の注目を集め、新たな発想を掻き立てることができる最高レベルの重要情報が紹介されることになっています。
また今回からは、各種のテーマに新たな光を当て、日本の製薬業界で重要な役割を担っている人々をひきつけるため、学会の名称も新しくなります。

会議のハイライト

戦略的なテーマに関する討議：

• 日本における抗体開発の将来像−他国に比べ著しく遅れているといわれるこの分野の現状を分析し、新たな可能性を模索します
• 生産性の低下とリーダーシップ−買収や合併の有効性について検討し、日本の医療が対応できていないニーズを探ります
• グローバル化と地域化−アジア新興市場への参入問題について考え、拡大するアジア市場における日本の立ち位置を探ります
• 日本におけるジェネリックおよびバイオジェネリック医薬品の影響−政府の圧力と業界内のさまざまな動きを分析します

科学分野のセッション：

• iPS細胞/再生医療
• 分子標的治療
• 次世代抗体とタンパク質科学
• 個別化医療と診断
• RNA干渉(RNAi)技術の開発
• 新製品開発強化のためのオープンな技術革新/研究開発戦略
• 新興市場における新薬開発と治験
• 日本のバイオテクノロジー技術

Strengthen your Pipeline with New Opportunities in Open Innovation, Next Generation Biologics, Personalized Medicine, Stem Cells and Targeted Cancer Therapies

The Drug & Biologics Japan event aims to address the changing paradigms in Japan's pharmaceutical industry - shifting from small molecules to antibody/protein science and stem cells, from traditional drug discovery to molecularly targeted therapies and personalized medicine strategies. You will hear from over 50 speakers from 10 countries, including USA, UK, Japan, Germany, Belgium, Switzerland, Australia, Israel, China and India, who will share their current strategies, ongoing developments and proven successes.

Network with over 50 speakers and get first-hand information on:

• Transforming ideas into innovation and bridge the gap between inspiration and implementation
• Alternative scaffolds, conjugates or bispecific antibodies - How you can leapfrog into the current developments
• Personalized medicine, pharmacogenomics, biomarkers and diagnostics - Overcoming challenges to implementation
• Science, technology and therapeutic applications of iPS cells, ES cells and adult stem cells - Industry-academia collaborations to bring therapies faster-to-market
• Targeting ARQ197, CICs, P2X7 and other novel molecular targets - Working to towards a breakthrough in cancer therapeutics

Open Innovation
Governments in various parts of the world are actively supporting innovation - more specifically, Open Innovation. It has become increasingly necessary for inventors and their firms to exploit information and capabilities outside the firm in order to combine one's own resources with resources from the external environment. This session will explore how "open innovation" is influencing Japanese pharma and healthcare industry to modify their innovation strategies to enhance their creativity and productivity.

Next Generation Biologics
Covering topics on ADC, alternative scaffolds, bispecific and multispecific antibodies, immunogenicity, preclinical and clinical development updates, the session offers insights into the current stateof- the-art developments in next generation biologics from around the world. Japanese pharmaceutical and biotech companies already in the space or planning to enter the space cannot afford to miss this session.

Stem Cells
Stem cells is one of the fastest growing areas of research throughout the world, and Japan is ranked among the top research centers for stem cell science and technology. This session will bring together experts from academia and industry to discuss the science and therapeutic applications of iPS cells, ES cells, mesenchymal stem cells etc.

Personalized Medicine & Biomarkers
Personalized medicine or "order-made medicine" as it is known in Japan, is a major initiative not only by the Japanese government but also throughout the world's pharmaceutical industry. In this session, we will hear from leading pharmaceutical companies like Wyeth and AstraZeneca on how they are incorporating personalized medicine and biomarkers in their drug development strategies.

Molecularly Targeted Cancer Therapies
A new frontier in cancer drug development has emerged - where scientists are now focusing on developing drugs that target the molecular alterations involved in the biological pathways in cancer. Hear from Kyowa Hakko Kirin, Daiichi Sankyo, RIKEN, BioSceptre and ArQule as they present their latest therapeutic developments that aim to block the growth and spread of cancer by interfering with specific molecules involved in tumor growth and progression.